NCT03910660: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Sponsor: BioXcel Therapeutics Inc. Phase: PHASE1. Conditions: Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma